Last reviewed · How we verify
Experimental 23-valent Pneumococcal
Experimental 23-valent Pneumococcal is a Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved.
At a glance
| Generic name | Experimental 23-valent Pneumococcal |
|---|---|
| Sponsor | Sinovac Biotech Co., Ltd |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- Clinical Trial of PCV24 in Infants Aged 2-23 Months (PHASE1)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months (PHASE2)
- Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia (PHASE2)
- Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above (PHASE1)
- Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
- Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental 23-valent Pneumococcal CI brief — competitive landscape report
- Experimental 23-valent Pneumococcal updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about Experimental 23-valent Pneumococcal
What is Experimental 23-valent Pneumococcal?
Experimental 23-valent Pneumococcal is a Biologic drug developed by Sinovac Biotech Co., Ltd.
Who makes Experimental 23-valent Pneumococcal?
Experimental 23-valent Pneumococcal is developed and marketed by Sinovac Biotech Co., Ltd (see full Sinovac Biotech Co., Ltd pipeline at /company/sinovac-biotech-co-ltd).
What development phase is Experimental 23-valent Pneumococcal in?
Experimental 23-valent Pneumococcal is FDA-approved (marketed).
Related
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing